Cited by 129Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Alzheimer’s disease as oligomeropathy

Ono, Kenjiro·2018·Neurochemistry International

Abstract

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder and is characterized by pathological aggregates of amyloid β-protein (Aβ) and tau protein. On the basis of genetic evidence, biochemical data, and animal models, Aβ has been suggested to be responsible for the pathogenesis of AD (the amyloid hypothesis). Aβ molecules tend to aggregate to form oligomers, protofibrils, and mature fibrils. Although mature fibrils in the final stage have been thought to be the cause of AD pathogenesis, recent studies using synthetic Aβ peptides, a cell culture model, Aβ precursor protein transgenic mice models, and human samples, such as cerebrospinal fluids and postmortem brains of AD patients, suggest that pre-fibrillar forms (oligomers of Aβ) are more deleterious than are extracellular fibril forms. Based on this recent evidence showing that oligomers have a central role in the pathogenesis of AD, the term "oligomeropathy" could be used to define AD and other protein-misfolding diseases. In this review, I discuss recent developments in the "oligomer hypothesis" including our research findings regarding the pathogenesis of AD.

Integrity signals

Registry

Crossref · 10.1016/j.neuint.2017.08.010

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Oligomeric Aβ peptides are more destructive than Aβ monomers and fibrillar forms in the brain.

    “it has been observed that oligomeric Aβ peptides are more destructive than Aβ monomers and fibrillar forms in the brain [132,133].”

    From Beneficial Effects of Spirulina Consumption on Brain Health (2022) · cites this paper as [132]

The citation lists haven’t been fetched yet

References 173 · Cited by 129

Authors
Ono, K.
Affiliations
SHOWA Medical University (JP)
Corresponding author
Ono, Kenjiro
Venue
Neurochemistry International
Publisher
Elsevier BV
Published
2018-10
Volume
119
Pages
57-70
ISSN
0197-0186 (ISSN-L)
OpenAlex
W2750472319
Cited by
129
References
173
Citations by year
2026: 9 · 2025: 15 · 2024: 14 · 2023: 13 · 2022: 17 · 2021: 18 · 2020: 19 · 2019: 13 · 2018: 8 · 2017: 3
FWCI
1.48
Type
journal article
Language
en
Open access
closed
Locations
  • Neurochemistry International (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Grant-in-Aid for Young Scientists (22790815)
  • Scientific Research (26461266)
  • Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan
  • Japan Health Sciences Foundation
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Novartis Foundation for Gerontological Research
  • Department of Medicine at Showa University
  • Takeda Science Foundation
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta, amyloid oligomers, amyloid hypothesis, protein misfolding, tau protein, amyloid fibrils, neurodegeneration, pathogenesis
MeSH terms
Alzheimer Disease, Animals, Brain, Disease Models, Animal, Humans, Peptide Fragments, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review